Phase I multicentre, open-label, dose-escalating study of PM00104 administered as 1 hour intravenous infusion every 3 weeks in subjects with advanced solid tumour or lymphoma
Latest Information Update: 13 Jul 2012
At a glance
- Drugs PM 00104 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 26 Jul 2005 New trial record.